Checkpoint inhibitor

The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Announces Five New Investments Supporting Next Generation Cell Therapies and a Novel Immune Checkpoint Inhibitor

Retrieved on: 
Thursday, April 22, 2021
Branches of biology, Medical specialties, Clinical medicine, Immune system, Cancer immunotherapy, Cell biology, Immunotherapy, Virotherapy, T cell, Checkpoint inhibitor, Molecular oncology

LLS TAP due diligence and investment credibility can help companies raise needed funds to drive clinical-focused research forward.

Key Points: 
  • LLS TAP due diligence and investment credibility can help companies raise needed funds to drive clinical-focused research forward.
  • Off-the-shelf CAR T-cell therapies use healthy donor T cells instead of reengineering a patient\'s own cells.
  • The company\'s Artificial Immune Modulation, or AIM platform, does not rely on genetic manipulation of T cells.
  • Checkpoint inhibitors work by \'releasing the brake\' from the body\'s own immune cells so that they can effectively attack cancer cells.

Roswell Park, Wilmot Cancer Institute Collaborate on First Large Study of Immunotherapy in Black Cancer Patients

Retrieved on: 
Wednesday, April 21, 2021
Cancer treatments, Clinical medicine, Medicine, Cancer immunotherapy, Antineoplastic drugs, Breakthrough therapy, Virotherapy, Checkpoint inhibitor, Immune system, Immunotherapy, Oncology, Pembrolizumab

b'BUFFALO and ROCHESTER, N.Y., April 21, 2021 /PRNewswire/ --A new collaboration will help oncologists learn whether Black and white cancer patients respond differently to a game-changing immunotherapy treatment, and seeks to improve the safety and effectiveness of these newer drugs in diverse populations.\nOur findings show there may be a particular benefit to these immunotherapies for cancer patients of African ancestry.\nCheckpoint inhibitors such as nivolumab (Opdivo) and pembrolizumab (Keytruda) have become standard care for 16 different types of cancer, both early and advanced-stage.

Key Points: 
  • b'BUFFALO and ROCHESTER, N.Y., April 21, 2021 /PRNewswire/ --A new collaboration will help oncologists learn whether Black and white cancer patients respond differently to a game-changing immunotherapy treatment, and seeks to improve the safety and effectiveness of these newer drugs in diverse populations.\nOur findings show there may be a particular benefit to these immunotherapies for cancer patients of African ancestry.\nCheckpoint inhibitors such as nivolumab (Opdivo) and pembrolizumab (Keytruda) have become standard care for 16 different types of cancer, both early and advanced-stage.
  • They work by blocking signals in the immune system, clearing a path for the body\'s natural T cells to kill cancer.\nFew people of African ancestry participated in the original clinical trials to evaluate these treatments.
  • The Roswell Park-Wilmot collaborators plan to collect data that will allow them to investigate side effects, toxicities and outcomes among people of African ancestry who take immune checkpoint inhibitors.\n"Checkpoint inhibitors have largely not been studied in Black cancer patients, but our recent findings show that there may be a particular benefit to these immunotherapies for cancer patients of African ancestry across a variety of cancer types," says Christine Ambrosone, PhD , Chair of Cancer Prevention & Control at Roswell Park and a Co-Investigator on the study.\n"Because Black cancer patients tend to have a prevalence of what we call \'exhausted,\' nonfunctional T cells, we realized they may be more likely to do well on immune checkpoint inhibitors, which target the exhausted T cells to revive them and restore their ability to fight cancer cells," says Song Yao, PhD , Professor of Oncology in Roswell Park\'s Department of Cancer Prevention and Control, Co-Principal Investigator on the study.\nThe team, including Co-Principal Investigator Charles Kamen, PhD, MPH , and Co-Investigator Gary Morrow, PhD, MS , from the University of Rochester, have designed a large national study known as the DiRECT Cohort that will seek to enlist 600 Black patient volunteers and 1,200 white cancer patients of European ancestry.\nThe Wilmot/University of Rochester team will leverage its position as a hub for the National Community Oncology Research Program of NCORP.
  • Dr. Morrow, a Dean\'s Professor of Surgery at UR, is co-Principal Investigator for the NCORP program.\n'

Hankyung.com's Introduces: COSMAX's Skin Microbiome Research Becomes First of Its Kind to Be Published in International Scientific Journal

Retrieved on: 
Monday, April 19, 2021
Immune system, Cancer immunotherapy, Branches of biology, Microbiome, Checkpoint inhibitor, Spermidine, Immune checkpoint, Microbiomes, Bacteriology

It was also discovered that spermidine, which is created during the metabolic process, directly impacts skin anti-aging.

Key Points: 
  • It was also discovered that spermidine, which is created during the metabolic process, directly impacts skin anti-aging.
  • "The technology super gap will be used in the next generation of anti-aging cosmetics and biomaterials in the global market.
  • "\nCOXMAX is expected to expand the application of the skin microbiome to various products.
  • It focuses on developing the next waves of innovative therapeutics in immune-oncology through diverse modalities of microbiome and novel target immune checkpoint inhibitors.\n'

TriSalus Life Sciences Presents Data at American Association of Cancer Research Showing Reduced Liver Tumor Burden from Toll-Like Receptor Agonists

Retrieved on: 
Wednesday, April 14, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Immunology, Medical specialties, Immune system, Clinical medicine, TLR9, Cancer immunotherapy, CpG Oligodeoxynucleotide, Checkpoint inhibitor

TriSalus intends to pursue multiple solid tumor indications with investigational SD-101 and acquire other immuno-oncology agents to combine with its proprietary Pressure-Enabled Drug Delivery technology for the administration of therapeutics intravascularly into visceral organ solid tumors.

Key Points: 
  • TriSalus intends to pursue multiple solid tumor indications with investigational SD-101 and acquire other immuno-oncology agents to combine with its proprietary Pressure-Enabled Drug Delivery technology for the administration of therapeutics intravascularly into visceral organ solid tumors.
  • In combination with checkpoint inhibitors, TriSalus\xe2\x80\x99 focus is to reprogram the dominant immunosuppressive cell population in liver and pancreatic tumors.
  • Regional administration of Class C CpG Oligodeoxynucleotides results in superior intrahepatic TLR9 activation and immunomodulation compared to systemic infusion.
  • \xe2\x80\x9cDevelopment of TLR9 Agonists for Cancer Therapy.\xe2\x80\x9d The Journal of Clinical Investigation 117 (5): 1184\xe2\x80\x9394.\nJain, Rakesh K. 1994.

Alpine Immune Sciences Presents Clinical and Preclinical Oncology Program Updates at AACR Virtual Annual Meeting I

Retrieved on: 
Monday, April 12, 2021
Oncology, Health, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Immune system, Clinical medicine, Medicine, Cancer immunotherapy, Checkpoint inhibitor, Programmed cell death protein 1, Application-Layer Protocol Negotiation, Branches of biology, Alpine’s Directed Evolution Platform, ALPN-202, Alpine Immune Sciences, Inc.

Preclinical studies of ALPN-202 have successfully demonstrated superior efficacy in tumor models compared to checkpoint inhibition alone.

Key Points: 
  • Preclinical studies of ALPN-202 have successfully demonstrated superior efficacy in tumor models compared to checkpoint inhibition alone.
  • NEON-1 (NCT04186637), a Phase 1 study of ALPN-202 in patients with advanced malignancies, is currently enrolling.
  • Alpine is also targeting the initiation of NEON-2, a Phase 1 combination study of ALPN-202 and a PD-1 inhibitor, later this year.\nAlpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics.
  • Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development.

InterVenn’s Glycoproteomic-based Biomarker Signature Successfully Predicts Favorable Outcomes in Metastatic Malignant Melanoma Patients Treated with Checkpoint Inhibitors

Retrieved on: 
Monday, April 12, 2021
Data management, Biotechnology, Technology, Health, General Health, Pharmaceutical, Oncology, Research, Software, Genetics, Science, Medicine, Clinical medicine, Medical specialties, Cancer immunotherapy, Cancer, Melanoma, Checkpoint inhibitor, Biopsy

b'InterVenn Biosciences , the leader in glycoproteomics, announced today that it has developed a glycoproteomics-based signature that accurately predicts which malignant melanoma patients will respond to checkpoint inhibitor therapy.

Key Points: 
  • b'InterVenn Biosciences , the leader in glycoproteomics, announced today that it has developed a glycoproteomics-based signature that accurately predicts which malignant melanoma patients will respond to checkpoint inhibitor therapy.
  • InterVenn\xe2\x80\x99s assay, performed via blood-based liquid biopsy as opposed to a tumor tissue sample, demonstrated that patients who test positive for the InterVenn signature have a 9-fold higher likelihood of responding to checkpoint inhibitors compared to those who test negative.
  • However, only approximately 1 in 3 patients will respond, exposing those not deriving any benefit needlessly to potentially serious adverse events.
  • For more information about InterVenn Biosciences, please visit the company\xe2\x80\x99s website .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210412005237/en/\n'

GeneLeap Presents New Preclinical Data for Hydrogel Encapsulated TLR9 Agonist at AACR 2021

Retrieved on: 
Wednesday, April 14, 2021
Branches of biology, Medicine, Health sciences, Clusters of differentiation, Pharmacodynamics, Cancer immunotherapy, Immune system, TLR9, Checkpoint inhibitor, Agonist, Hydrogel

As aninnate immunestimulator, TLR9 agonist canbecombined with checkpoint inhibitors to increase itsanti-tumor effects.

Key Points: 
  • As aninnate immunestimulator, TLR9 agonist canbecombined with checkpoint inhibitors to increase itsanti-tumor effects.
  • Local injection of the TLR9 agonist is well-tolerated but the drug can degrade in the local tissues or dissipate from the site of action rapidly, resulting in reducedefficacy.
  • GeneLeap\'s researchers have conducted preclinical studies in a mouse tumor model to examine whether a single dose of Hydrogel encapsulated TLR9 agonist can be effective over a longer period in immune activation without toxicity.\nThe current preclinical study showed that a single administration of hydrogel encapsulated TLR9 agonist demonstrates tumor growth inhibition and non-toxicity similar to that of a multiple dose of TLR9 agonist without hydrogel encapsulation.
  • This indicates that for those patients who are resistant or refractory to checkpoint inhibitors, hydrogel encapsulated TLR9 agonist could enhance the immune response to checkpoint inhibitors for a longer time.

Phio Pharmaceuticals Presents Positive In Vivo Data Showing Strong Tumor Control for the Intratumoral Delivery of INTASYL™ RNAi Targeting PD-1

Retrieved on: 
Saturday, April 10, 2021
Immune system, Immunology, Medical specialties, Clinical medicine, Cancer immunotherapy, Phio Pharmaceuticals, Immune checkpoint, Programmed cell death protein 1, Checkpoint inhibitor

The Company believes these data further support the potential for INTASYL mPH-762 to provide strong local immune checkpoint blockade (ICB), without the dose immune-related adverse effects (irAEs) seen with systemic ICB antibody therapy.

Key Points: 
  • The Company believes these data further support the potential for INTASYL mPH-762 to provide strong local immune checkpoint blockade (ICB), without the dose immune-related adverse effects (irAEs) seen with systemic ICB antibody therapy.
  • "We are pleased to announce new in vivo data today that show INTASYL mPH-762 offered strong tumor control in Hepa 1-6 and CT26 models, which are PD-1 responsive and PD-1 refractory models, respectively.
  • "These data further support our excitement around this asset andto bring PH-762 to patients, starting with our first clinical study later this year."
  • Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL) therapeutic platform.

Data at AACR Demonstrate Growing Clinical Utility of Guardant Health Liquid Biopsies in the Treatment and Management of Advanced Cancers

Retrieved on: 
Saturday, April 10, 2021
Oncology, Medical Supplies, Health, Clinical trials, Pharmaceutical, Biotechnology, Clinical medicine, Medicine, Branches of biology, DNA, Oncology, Liquid biopsy, Cancer, Checkpoint inhibitor, Circulating tumor DNA, Helmy Eltoukhy

The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes, and lower healthcare costs across all stages of the cancer care continuum.

Key Points: 
  • The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes, and lower healthcare costs across all stages of the cancer care continuum.
  • Guardant Health has commercially launched liquid biopsy-based Guardant360, Guardant360 CDx, and GuardantOMNI tests for advanced-stage cancer patients, and Guardant Reveal test for early-stage cancer patients.
  • These forward-looking statements should not be relied upon as representing Guardant Healths views as of any date subsequent to the date of this press release.
  • Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade.

Freenome Presents Data Revealing Signatures of Immune Checkpoint Inhibitor Treatment Response Found to Be Common Across Kidney, Melanoma, and Lung Cancers

Retrieved on: 
Saturday, April 10, 2021
Research, Technology, Genetics, Other Technology, Software, Biotechnology, Health, Science, Oncology, Other Science, Clinical medicine, Medicine, Cancer treatments, Cancer immunotherapy, Biomarkers, Checkpoint inhibitor, Immune system, Cancer, Lung cancer, Cancer biomarker

Plasma samples from patients with kidney (n=21), melanoma (n=14) or non-small cell lung cancer (n=91) revealed signatures of immune checkpoint inhibition treatment response found to be common across all three cancer types.

Key Points: 
  • Plasma samples from patients with kidney (n=21), melanoma (n=14) or non-small cell lung cancer (n=91) revealed signatures of immune checkpoint inhibition treatment response found to be common across all three cancer types.
  • A subsequent longitudinal analysis on a subset of lung cancer patients also identified markers for treatment response.
  • These results show the promise of our multiomics platform, which combines signatures from both tumor- and non-tumor-derived sources, commented Mike Nolan, Chief Business Officer of Freenome.
  • A blood-based test that can predict and monitor treatment response would help address the clear need for improved biomarkers for cancer patients undergoing immune checkpoint inhibitor treatment, where responses are highly variable.